,
Kellert, Lars
Grau, Armin
Pezzini, Alessandro
Debette, Stéphanie
Leys, Didier
Caso, Valeria
Thijs, Vincent N.
Bersano, Anna
Touzé, Emmanuel
Tatlisumak, Turgut
Traenka, Christopher
Lyrer, Philippe A.
Engelter, Stefan T.
Metso, Tiina M.
Grond-Ginsbach, Caspar
Kloss, Manja
Article History
Received: 4 December 2017
Revised: 8 February 2018
Accepted: 12 February 2018
First Online: 24 February 2018
Compliance with ethical standards
:
: LK has received funding for travel and/or speaker honoraria from Bayer Vital, Boehringer Ingelheim, Bristal Myers Squibb, Daiichi Sankyo, and Pfizer. AG, AP, SD, DL, AB, TT, CT, CGG, MK report no disclosures. TMM has received funding from the Finnish Medical Foundation, Helsinki University Central Hospital Research Fund, Helsinki University Medical Foundation, Orion Farmos Research Foundation, Päivikki and Sakari Sohlberg Foundation, Maire Taponen Foundation, the Lilly Foundation, Paavo Ilmari Ahvenainen Foundation, Aarne and Aili Turunen Foundation, Aarne Koskelo Foundation, the Maud Kuistila Memorial Foundation, Emil Aaltonen Foundation, Finnish Brain Foundation, and Alfred Kordelin Foundation. VC has served as speaker for Boehringer Ingelheim, Sanofi, and Pfizer. VNT has received funding for travel or speaker honoraria from Bayer, Boehringer Ingelheim, Pfizer Inc and Medtronic; he has served on scientific advisory boards for Shire, Bayer, Pfizer and Boehringer Ingelheim and on the editorial board of Stroke. He is an associate editor of Acta Neurologica Belgica. He has received honoraria for being on the steering committee of the AX200 trial (SYGNIS). He has received research support from FWO Flanders. AB has received funding for travel and congresses participations from Shire, Boehringer Ingelheim, and Sanofi-aventis. ET has served on scientific advisory boards for Bayer Schering Pharma, Pfizer, BMS, and Shire; has received speaker honoraria from Boehringer Ingelheim, Bayer Schering Pharma, Pfizer, BMS, and Shire; has received funding for travel from Astra Zeneca and BMS; he serves as assistant editor for Stroke; and has received research support from the French Ministry of Health. PAL has served on scientific advisory boards for Bayer Schering Pharma, and Boehringer Ingelheim; has received funding for travel or speaker honoraria from Bayer Schering Pharma, Boehringer Ingelheim, and Shire plc; he serves as Co-Editor for Neurologie und Psychiatrie and on the editorial board of Swiss Archives of Neurology and Psychiatry; and has received research support from AstraZeneca, Boehringer Ingelheim, Sanofi-aventis, PhotoThera, the Swiss National Science Foundation, and the Swiss Heart Foundation. STE has received funding for travel or speaker honoraria from Bayer, Boehringer Ingelheim, Pfizer Inc, Sanofi-aventis, and Shire plc; he has served on scientific advisory boards for Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb, and Pfizer and on the editorial board of Stroke. He has received research support from the Kaethe-Zingg-Schwichtenberg-Fonds of the Swiss Academy of Medical Sciences, the Swiss Heart Foundation, and Swiss National Science Foundation.
: The CADISP study protocol () was approved by the relevant local authorities of all participating centers and is conducted according to the national rules concerning ethics committee approval and informed consent.